UA106194C2 - Диагностика и лечение рака с применением антитела к ereg - Google Patents

Диагностика и лечение рака с применением антитела к ereg

Info

Publication number
UA106194C2
UA106194C2 UAA200904419A UAA200904419A UA106194C2 UA 106194 C2 UA106194 C2 UA 106194C2 UA A200904419 A UAA200904419 A UA A200904419A UA A200904419 A UAA200904419 A UA A200904419A UA 106194 C2 UA106194 C2 UA 106194C2
Authority
UA
Ukraine
Prior art keywords
diagnosis
cancer
treatment
ereg antibody
antibody
Prior art date
Application number
UAA200904419A
Other languages
English (en)
Ukrainian (uk)
Inventor
Хироюки АБУРАТАНИ
Хиротака ИТО
Кенджи Йошида
Original Assignee
Чугей Сейяку Кабусики Кайся
Дзе Юниверсити Оф Токио
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Чугей Сейяку Кабусики Кайся, Дзе Юниверсити Оф Токио filed Critical Чугей Сейяку Кабусики Кайся
Publication of UA106194C2 publication Critical patent/UA106194C2/ru

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/485—Epidermal growth factor [EGF] (urogastrone)

Abstract

Изобретение относится к применению антитела, которое связывается с белком эпирегулина (EREG), как противоракового агента. Также данное изобретение относится к моноклональному антителу, которое специфически связывается с белком EREG.
UAA200904419A 2006-10-12 2007-10-12 Диагностика и лечение рака с применением антитела к ereg UA106194C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006278819 2006-10-12
PCT/JP2007/069988 WO2008047723A1 (en) 2006-10-12 2007-10-12 Diagnosis and treatment of cancer using anti-ereg antibody

Publications (1)

Publication Number Publication Date
UA106194C2 true UA106194C2 (ru) 2014-08-11

Family

ID=39313954

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200904419A UA106194C2 (ru) 2006-10-12 2007-10-12 Диагностика и лечение рака с применением антитела к ereg

Country Status (16)

Country Link
US (1) US9017684B2 (ru)
EP (1) EP2070548B1 (ru)
JP (2) JP5687822B2 (ru)
KR (1) KR101493779B1 (ru)
CN (2) CN101594883B (ru)
AU (1) AU2007312367B2 (ru)
BR (1) BRPI0719202A2 (ru)
CA (1) CA2665528C (ru)
IL (2) IL197914A (ru)
MX (1) MX2009003738A (ru)
MY (1) MY162056A (ru)
NO (1) NO20091842L (ru)
NZ (2) NZ601022A (ru)
RU (2) RU2537245C2 (ru)
UA (1) UA106194C2 (ru)
WO (1) WO2008047723A1 (ru)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA106194C2 (ru) 2006-10-12 2014-08-11 Чугей Сейяку Кабусики Кайся Диагностика и лечение рака с применением антитела к ereg
WO2009051974A1 (en) * 2007-10-17 2009-04-23 Nuvelo, Inc. Antibodes to cll-1
WO2009149363A1 (en) * 2008-06-05 2009-12-10 Medical College Of Wisconsin, Inc. Three dimensional tissues for high-throughput assays
JP5883653B2 (ja) * 2009-03-10 2016-03-15 ベイラー リサーチ インスティテュートＢａｙｌｏｒ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ 抗原提示細胞ターゲティング抗ウイルスワクチン
CN102448989B (zh) 2009-03-10 2015-09-30 贝勒研究院 抗-cd40抗体及其用途
JP5808052B2 (ja) 2009-05-29 2015-11-10 中外製薬株式会社 Ｅｇｆファミリーリガンドのアンタゴニストを成分とする医薬組成物
IT1397083B1 (it) * 2009-12-04 2012-12-28 Biouniversa Srl Marcatore biochimico serico
SG181938A1 (en) 2009-12-25 2012-07-30 Pharmalogicals Res Pte Ltd Method for searching and screening for target of anti-cancer agent using non-human animal model having nog established cancer cell line transplanted therein
KR101637138B1 (ko) 2010-02-24 2016-07-06 이뮤노젠 아이엔씨 엽산염 수용체 1 항체와 면역접합체 및 이들의 용도
JP5858984B2 (ja) * 2010-04-18 2016-02-10 イェダ リサーチ アンド デベロップメント カンパニー リミテッド ＥｒｂＢ／ＥｒｂＢリガンドに関連する疾患を治療するための分子及びその分子を使用する方法
CN103328626B (zh) 2010-10-06 2017-02-08 中外制药株式会社 癌干细胞群及其制备方法
EP2637692A4 (en) * 2010-11-12 2014-09-10 Scott & White Healthcare ANTIBODIES TO THE ENDOTHELIAL TUMOR MARKER 8
EP2663579B1 (en) 2011-01-14 2017-04-26 The Regents of the University of California Therapeutic antibodies against ror-1 protein and methods for use of same
EP2694106B1 (en) 2011-04-01 2017-12-13 ImmunoGen, Inc. Methods for increasing efficacy of folr1 cancer therapy
AR085484A1 (es) 2011-04-06 2013-10-02 Lilly Co Eli ANTICUERPOS QUE SE UNEN A TGF-a Y EPIREGULINA
TWI687439B (zh) 2011-06-30 2020-03-11 中外製藥股份有限公司 異源二聚化多胜肽
US10018630B2 (en) 2011-09-07 2018-07-10 Chugai Seiyaku Kabushiki Kaisha Cancer stem cell isolation
JP6291254B2 (ja) 2011-10-28 2018-03-14 中外製薬株式会社 癌幹細胞特異的分子
TWI593705B (zh) * 2011-12-28 2017-08-01 Chugai Pharmaceutical Co Ltd Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient
US9163090B2 (en) 2012-05-07 2015-10-20 Cellerant Therapeutics, Inc. Antibodies specific for CLL-1
SG11201500938XA (en) 2012-08-31 2015-04-29 Immunogen Inc Diagnostic assays and kits for detection of folate receptor 1
US10766960B2 (en) 2012-12-27 2020-09-08 Chugai Seiyaku Kabushiki Kaisha Heterodimerized polypeptide
WO2014144170A1 (en) * 2013-03-15 2014-09-18 The Cleveland Clinic Foundation In-vitro method for monoclonal antibody production using non-human act1 -deficient mice
US9657098B2 (en) * 2013-03-15 2017-05-23 Intrinsic Lifesciences, Llc Anti-hepcidin antibodies and uses thereof
AU2014299916A1 (en) * 2013-06-24 2015-12-24 Chugai Seiyaku Kabushiki Kaisha Therapeutic agent comprising humanized anti-Epiregulin antibody as active ingredient for non-small-cell lung carcinoma excluding adenocarcinoma
AU2014312086B2 (en) 2013-08-30 2020-03-12 Immunogen, Inc. Antibodies and assays for detection of folate receptor 1
US10286058B2 (en) 2014-01-13 2019-05-14 Baylor Research Institute Vaccines against HPV and HPV-related diseases
EP3102611A4 (en) * 2014-02-03 2017-08-23 Cangene Corporation Humanized beta-amyloid binding molecules and uses thereof
CN106459089B (zh) 2014-02-18 2021-01-08 赛威德医疗公司 生物素变体、链霉亲和素突变体以及它们的应用
WO2017037707A1 (en) * 2015-09-02 2017-03-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Antibodies specific to human t-cell immunoglobulin and itim domain (tigit)
MA42844A (fr) 2015-09-17 2018-07-25 Immunogen Inc Combinaisons thérapeutiques comprenant des immunoconjugués anti-folr1
CN109983024A (zh) 2016-11-25 2019-07-05 赛威德医疗公司 清除剂
WO2019048040A1 (en) 2017-09-06 2019-03-14 Ganymed Pharmaceuticals Gmbh ANTIBODIES USEFUL IN THE DIAGNOSIS OF CANCER
US10610585B2 (en) 2017-09-26 2020-04-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions for treating and preventing HIV
WO2023168087A1 (en) * 2022-03-04 2023-09-07 Yale University Methods and compositions for treating and preventing fibrosis

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58201994A (ja) 1982-05-21 1983-11-25 Hideaki Hagiwara 抗原特異的ヒト免疫グロブリンの生産方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5190858A (en) 1989-02-01 1993-03-02 Oncogene Science, Inc. Monoclonal antibodies directed to epitopes of human transforming growth factor--α and uses thereof
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ATE185601T1 (de) 1990-07-10 1999-10-15 Cambridge Antibody Tech Verfahren zur herstellung von spezifischen bindungspaargliedern
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
ATE181571T1 (de) 1991-09-23 1999-07-15 Medical Res Council Methoden zur herstellung humanisierter antikörper
JPH07501451A (ja) 1991-11-25 1995-02-16 エンゾン・インコーポレイテッド 多価抗原結合タンパク質
ATE463573T1 (de) 1991-12-02 2010-04-15 Medimmune Ltd Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
EP0746609A4 (en) 1991-12-17 1997-12-17 Genpharm Int NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES
WO1993019172A1 (en) 1992-03-24 1993-09-30 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
AU675661B2 (en) 1992-07-24 1997-02-13 Abgenix, Inc. Generation of xenogeneic antibodies
US5648267A (en) 1992-11-13 1997-07-15 Idec Pharmaceuticals Corporation Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
CA2164295A1 (en) 1993-06-04 1994-12-22 Toshi Komurasaki Human-derived tumor cell growth inhibitors
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
AU690171B2 (en) 1993-12-03 1998-04-23 Medical Research Council Recombinant binding proteins and peptides
US5994524A (en) 1994-07-13 1999-11-30 Chugai Seiyaku Kabushiki Kaisha Polynucleotides which encode reshaped IL-8-specific antibodies and methods to produce the same
EP0822830B1 (en) 1995-04-27 2008-04-02 Amgen Fremont Inc. Human anti-IL-8 antibodies, derived from immunized xenomice
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
WO1999054342A1 (en) 1998-04-20 1999-10-28 Pablo Umana Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
EP2270148A3 (en) 1999-04-09 2011-06-08 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
AU784045B2 (en) 1999-06-25 2006-01-19 Genentech Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
ES2620359T3 (es) 2000-10-06 2017-06-28 Kyowa Hakko Kirin Co., Ltd. Células que producen unas composiciones de anticuerpo
CU22979A1 (es) 2000-12-08 2004-09-09 Centro Inmunologia Molecular Combinación inmunoterapéutica para el tratamiento de tumores que sobre-expresan receptores con actividad quinasa en residuos de tirosina
AU2002307037B2 (en) 2001-04-02 2008-08-07 Biogen Idec Inc. Recombinant antibodies coexpressed with GnTIII
EP1514928B1 (en) 2002-06-05 2013-07-31 Chugai Seiyaku Kabushiki Kaisha Method for producing antibodies using baculoviruses
CN1678634A (zh) * 2002-06-28 2005-10-05 多曼蒂斯有限公司 免疫球蛋白单个变体抗原结合区及其特异性构建体
ES2542885T3 (es) 2003-01-22 2015-08-12 Roche Glycart Ag Constructos de fusión y uso de los mismos para producir anticuerpos con mayor afinidad de unión al receptor de Fc y función efectora
WO2004081047A1 (ja) * 2003-03-14 2004-09-23 Taisho Pharmaceutical Co., Ltd. モノクローナル抗体及びこれを産生するハイブリドーマ
US7195764B2 (en) 2003-04-14 2007-03-27 Arius Research Inc. Cancerous disease modifying antibodies
PT2311873T (pt) 2004-01-07 2018-11-20 Novartis Vaccines & Diagnostics Inc Anticorpo monoclonal específico para m-csf e respetivos usos
AU2005213464A1 (en) * 2004-02-06 2005-08-25 Wyeth Diagnosis and therapeutics for cancer
EP2208783A1 (en) 2004-12-22 2010-07-21 Chugai Seiyaku Kabushiki Kaisha Method of producing an antibody using a cell in which the function of fucose transporter is inhibited
CA2593697A1 (en) 2005-01-11 2006-07-20 Molecular Logix, Inc. Pan-her antagonists and methods of use
EP2281901B1 (en) 2005-08-02 2013-11-27 Eisai R&D Management Co., Ltd. Anti-tumour pharmaceutical composition with angiogenesis inhibitors
UA106194C2 (ru) 2006-10-12 2014-08-11 Чугей Сейяку Кабусики Кайся Диагностика и лечение рака с применением антитела к ereg
JP5808052B2 (ja) 2009-05-29 2015-11-10 中外製薬株式会社 Ｅｇｆファミリーリガンドのアンタゴニストを成分とする医薬組成物
GB0909906D0 (en) 2009-06-09 2009-07-22 Affitech As Antibodies
GB0909904D0 (en) 2009-06-09 2009-07-22 Affitech As Product
TWI593705B (zh) 2011-12-28 2017-08-01 Chugai Pharmaceutical Co Ltd Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient

Also Published As

Publication number Publication date
BRPI0719202A2 (pt) 2015-06-16
CN103396486A (zh) 2013-11-20
EP2070548B1 (en) 2017-01-18
NO20091842L (no) 2009-07-13
WO2008047723A1 (en) 2008-04-24
RU2014141151A (ru) 2016-05-10
CN101594883A (zh) 2009-12-02
US20090324491A1 (en) 2009-12-31
NZ601022A (en) 2014-09-26
AU2007312367A1 (en) 2008-04-24
RU2014141151A3 (ru) 2018-07-18
IL225386A (en) 2014-07-31
IL197914A0 (en) 2011-08-01
RU2537245C2 (ru) 2014-12-27
JP2015091796A (ja) 2015-05-14
AU2007312367B2 (en) 2012-09-06
CA2665528A1 (en) 2008-04-24
KR101493779B1 (ko) 2015-02-16
NZ576855A (en) 2012-08-31
KR20090079214A (ko) 2009-07-21
IL225386A0 (en) 2013-06-27
MY162056A (en) 2017-05-31
RU2009117669A (ru) 2010-11-20
EP2070548A1 (en) 2009-06-17
MX2009003738A (es) 2009-07-17
JPWO2008047723A1 (ja) 2010-02-25
IL197914A (en) 2014-07-31
CA2665528C (en) 2018-01-23
JP5687822B2 (ja) 2015-03-25
US9017684B2 (en) 2015-04-28
JP5992480B2 (ja) 2016-09-14
CN101594883B (zh) 2018-04-10
EP2070548A4 (en) 2010-09-01

Similar Documents

Publication Publication Date Title
UA106194C2 (ru) Диагностика и лечение рака с применением антитела к ereg
UA92505C2 (ru) Композиции на основе антитела против cd3
EA201100694A1 (ru) Антитело к cd38 человека и его применение
MX2009008430A (es) Anticuerpos anti-robo4 y sus usos.
UA109633C2 (uk) Антитіло людини проти тканинного фактора
UA113712C2 (xx) Антитіло до fap і способи його застосування
EP2103628A4 (en) MONOCLONAL ANTIBODY ANTI-CLAUDIN 3, AND TREATMENT AND DIAGNOSIS OF CANCER USING SUCH ANTIBODY
EP3461847A8 (en) Humanized antibodies to liv-1 and use of same to treat cancer
EA200970317A1 (ru) Комбинированное лечение опухолей, экспрессирующих cd38
MX2009004532A (es) Composiciones y metodos para unir esfingosina-1-fosfato.
EA201401107A1 (ru) Специфические антагонисты рецептора fgf-r4
EA200802182A1 (ru) Модифицированные гуманизированные антитела против интерлейкина-18
DK1893196T3 (da) Diarylhydantoin-forbindelse
EA200970210A1 (ru) Prlr-специфическое антитело и его применения
EA201070636A1 (ru) Ингибирование рецептора белка, стимулирующего макрофаги (ron), и способы его лечения
MA33470B1 (fr) Polythérapie à base d'un anticorps afucosylé anti-cd20 et de fludarabine et/ou mitoxantrone
NZ607588A (en) Antibodies against human TWEAK and uses thereof
EP2175879A4 (en) TREATMENT OF DISEASES ASSOCIATED WITH PRION PROTEIN
MA32288B1 (fr) Nouveaux anticorps utiles pour le traitement du cancer
UA99339C2 (ru) Антитело, которое специфично связывает человеческий tyrp1
PH12013502194A1 (en) Antibodies to egfl7 and methods for their use
MX2013002718A (es) Composiciones de anticuerpo anti-vegfr-3.
MX2007013108A (es) Reactivos que enlazan ccx-ckr2.
WO2008118324A3 (en) Composition and method of treating cancer with an anti-uroplakin ib antibody
UA98632C2 (ru) Антагонистические антитела к notch3 и их применение для профилактики и лечения связанных с notch3 заболеваний